Reduction of cell proliferation and potentiation of Fas-induced apoptosis by the selective kappa-opioid receptor agonist U50 488 in the multiple myeloma LP-1 cells

Abstract As opioid receptors modulate proliferation and apoptosis of immune cells, we hypothesized that they could reduce malignant haematopoietic cells. After screening, we selected the human multiple myeloma LP-1 cells which express mu- (MOP-) and kappa-opioid receptors (KOP-R). U50 488 produces a...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neuroimmunology Vol. 220; no. 1; pp. 69 - 78
Main Authors:	Kerros, Céline, Brood, Isabelle, Sola, Brigitte, Jauzac, Philippe, Allouche, Stéphane
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 30-03-2010 Elsevier
Subjects:	3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer - pharmacology 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer - therapeutic use Allergy and Immunology Analgesics, Non-Narcotic - pharmacology Analgesics, Non-Narcotic - therapeutic use Apoptosis Apoptosis - drug effects Apoptosis - immunology Cell Cycle Proteins - drug effects Cell Cycle Proteins - metabolism Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects Cell Survival - drug effects Cell Survival - physiology Down-Regulation - drug effects Down-Regulation - immunology Drug Evaluation, Preclinical fas Receptor - agonists Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - metabolism Humans Life Sciences Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Multiple Myeloma - physiopathology Neurology Opioid receptor Receptors, Opioid, kappa - agonists Receptors, Opioid, kappa - metabolism Resting Phase, Cell Cycle - drug effects Cell proliferation Opioid receptor Multiple myeloma Apoptosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract As opioid receptors modulate proliferation and apoptosis of immune cells, we hypothesized that they could reduce malignant haematopoietic cells. After screening, we selected the human multiple myeloma LP-1 cells which express mu- (MOP-) and kappa-opioid receptors (KOP-R). U50 488 produces a modest but significant decrease in viability associated with an arrest in the G0/G1 phase, but not antagonized by NorBNI and not associated with modulation of p21Cip1 , p27Kip1 or p53 expression. In contrast, no effect was observed with dynorphin, U69 593 and morphine. In conclusion, the anti-proliferative effects of U50 488 are not mediated by KOP-R in the LP-1 cells.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0165-5728 1872-8421
DOI:	10.1016/j.jneuroim.2010.01.010